- Open Access
Erratum to: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
© BioMed Central Ltd 2006
Published: 5 October 2006
The original article was published in Breast Cancer Research 2005 8:R4
It has been brought to our attention that some paragraphs in the Introduction and Discussion of our recent research article  show close similarities to paragraphs in recent publications by Oh et al.  and Holloway et al. . While these publications were referenced elsewhere in our paper, the paragraphs which show similarities were not specifically referenced.
We regret this and offer our apologies to the authors.
- Munzone E, Curigliano G, Rocca A, Bonizzic G, Renne G, Goldhirsch A, Nolè F: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research. 2006, 8: R4-10.1186/bcr1366.View ArticlePubMedGoogle Scholar
- Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol. 2001, 15: 1344-1359. 10.1210/me.15.8.1344.PubMedGoogle Scholar
- Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-down-regulation in breast cancer cells: the role of nuclear factor-B. Mol Endocrinol. 2004, 18: 1396-1410. 10.1210/me.2004-0048.View ArticlePubMedGoogle Scholar